share_log

HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $42

HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $42

HC Wainwright & Co.维持对Revance Therapeutics的买入,将目标价上调至42美元
Benzinga Real-time News ·  2023/01/26 06:15

HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $29 to $42.

HC Wainwright&Co.分析师Douglas Tsao维持Revance Treateutics(纳斯达克:RVNC)的买入,并将目标价从29美元上调至42美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发